Form 4: Outlook Therapeutics Director Granted Stock Options

Outlook Therapeutics Director Julia A. Haller received two grants of stock options totaling 345,382 shares as part of her compensation.

Summary

• Julia A. Haller, a Director of Outlook Therapeutics, Inc. (OTLK), was granted two tranches of stock options.
• On October 1, 2025, Ms. Haller received 286,734 stock options with an exercise price of $1.04. This grant is an annual award under the company's Non-Employee Director Compensation Policy and the 2024 Equity Incentive Plan, vesting fully on October 1, 2026, subject to continuous service.
• On October 3, 2025, an additional 58,648 stock options were granted with an exercise price of $1.06. These options were issued in lieu of $55,000 in cash fees payable under the Non-Employee Director Compensation Policy and vest in four equal quarterly installments, fully by September 30, 2026, subject to continuous service.
• Both option grants are subject to acceleration upon a Change in Control, as defined in the 2024 Plan, provided Ms. Haller maintains continuous service immediately prior to such event.
• Following these transactions, Ms. Haller directly beneficially owns 286,734 stock options from the first grant and 58,648 stock options from the second grant.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction related to director compensation. It is mildly positive as it aligns director interests with shareholder value through equity, but it does not indicate significant operational or financial news.

Positives

• The grants align the director's interests with shareholder value through equity compensation.
• The second grant of 58,648 options in lieu of $55,000 cash fees conserves company cash resources.

Negatives

• The options do not provide immediate cash compensation to the director.
• Potential future dilution for existing shareholders if the options are exercised, although this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is dependent on the future market price of Outlook Therapeutics' common stock, which may fall below the exercise price.
• Options are subject to forfeiture if the reporting person's continuous service to the Issuer terminates before the vesting dates.

Future Outlook

The stock options are subject to future vesting schedules, with full vesting for the annual grant on October 1, 2026, and for the cash-in-lieu grant by September 30, 2026. Both grants include provisions for accelerated vesting upon a Change in Control, indicating potential future corporate events could impact the timing of option exercisability.

Management Comments

• The options were granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan.
• The options are subject to the Reporting Person providing continuous service to the Issuer on the respective vesting dates.
• Shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to continuous service immediately prior to such event.

Industry Context

The granting of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, aiming to align the interests of board members with those of shareholders by providing an equity stake in the company's long-term performance.

Comparison to Industry Standards

• Equity compensation for non-employee directors, including stock options, is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotech, to attract and retain qualified board members.
• The use of an Equity Incentive Plan (2024 Plan) and a Non-Employee Director Compensation Policy are typical corporate governance structures for managing such awards, comparable to practices at companies like Biogen Inc. or Amgen Inc. in their director compensation frameworks.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from enhanced alignment of director incentives with long-term company performance.
• Employees: No direct impact mentioned, but the 2024 Equity Incentive Plan may also apply to other employees, indicating a broader equity compensation strategy.

Next Steps

• The stock options will vest according to their respective schedules (October 1, 2026, and September 30, 2026).
• The director may exercise the vested options at the specified exercise prices before their expiration dates (October 1, 2035, and October 3, 2035).

Key Dates

Keywords

Outlook Therapeutics, OTLK, Stock Options, Director Compensation, Equity Incentive Plan, Form 4, Insider Transaction, Corporate Governance